Jeremy D. Rubinstein

817 total citations
39 papers, 455 citations indexed

About

Jeremy D. Rubinstein is a scholar working on Oncology, Epidemiology and Hematology. According to data from OpenAlex, Jeremy D. Rubinstein has authored 39 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 10 papers in Epidemiology and 9 papers in Hematology. Recurrent topics in Jeremy D. Rubinstein's work include CAR-T cell therapy research (11 papers), Polyomavirus and related diseases (10 papers) and Cytomegalovirus and herpesvirus research (8 papers). Jeremy D. Rubinstein is often cited by papers focused on CAR-T cell therapy research (11 papers), Polyomavirus and related diseases (10 papers) and Cytomegalovirus and herpesvirus research (8 papers). Jeremy D. Rubinstein collaborates with scholars based in United States, Belgium and United Kingdom. Jeremy D. Rubinstein's co-authors include Patricia A. Trimmer, Maria Borland, James P. Bennett, Paula M. Keeney, Stella M. Davies, Lei Liu, Maureen M. O’Brien, Adam Nelson, Michael Grimley and José A. Cancelas and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jeremy D. Rubinstein

35 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeremy D. Rubinstein United States	13	198	119	109	91	67	39	455
Joanna Zurko United States	12	175 0.9×	73 0.6×	53 0.5×	26 0.3×	13 0.2×	24	412
Lucia Brunello Italy	17	74 0.4×	345 2.9×	81 0.7×	24 0.3×	175 2.6×	50	681
Shiyama Mudali United States	7	171 0.9×	89 0.7×	26 0.2×	16 0.2×	23 0.3×	7	480
A. Zincone Italy	7	331 1.7×	25 0.2×	35 0.3×	71 0.8×	89 1.3×	10	428
Adela Escudero Spain	13	233 1.2×	173 1.5×	28 0.3×	13 0.1×	106 1.6×	29	513
Lynn Stazzone United States	9	91 0.5×	82 0.7×	26 0.2×	152 1.7×	45 0.7×	10	530
Téreza Coman France	12	145 0.7×	92 0.8×	35 0.3×	23 0.3×	210 3.1×	29	501
Amin Daei Sorkhabi Iran	10	161 0.8×	92 0.8×	27 0.2×	36 0.4×	12 0.2×	22	374
Aila Sarkesh Iran	10	162 0.8×	74 0.6×	26 0.2×	35 0.4×	10 0.1×	20	361
Lorna Garnier France	12	47 0.2×	79 0.7×	55 0.5×	58 0.6×	17 0.3×	29	401

Countries citing papers authored by Jeremy D. Rubinstein

Since Specialization

Citations

This map shows the geographic impact of Jeremy D. Rubinstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy D. Rubinstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy D. Rubinstein more than expected).

Fields of papers citing papers by Jeremy D. Rubinstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy D. Rubinstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy D. Rubinstein. The network helps show where Jeremy D. Rubinstein may publish in the future.

Co-authorship network of co-authors of Jeremy D. Rubinstein

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy D. Rubinstein. A scholar is included among the top collaborators of Jeremy D. Rubinstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy D. Rubinstein. Jeremy D. Rubinstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xavier, Ana C., et al.. (2025). Posttransplant EBV‐Positive Smooth Muscle Tumors in Children, Adolescents, and Young Adults: A Multi‐Institution Experience. Pediatric Blood & Cancer. 72(6). e31678–e31678.

Li, Amanda M., Catherine Aftandilian, Susan I. Colace, et al.. (2024). A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 4204–4204.

LeBlanc, Francis, Erin H. Breese, Karen Burns, et al.. (2024). Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. British Journal of Haematology. 205(3). 1055–1066. 3 indexed citations

Grimley, Michael, Tom Leemhuis, José A. Cancelas, et al.. (2024). Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. American Journal of Transplantation. 24(9). 1634–1643. 13 indexed citations

Gross, Thomas G. & Jeremy D. Rubinstein. (2023). Post‐transplant lymphoproliferative disease in children, adolescents, and young adults. Hematological Oncology. 41(S1). 48–56. 6 indexed citations

Rubinstein, Jeremy D., et al.. (2023). Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults. Best Practice & Research Clinical Haematology. 36(1). 101446–101446. 17 indexed citations

Phillips, Christine L., Christa Krupski, Christopher E. Dandoy, et al.. (2023). Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. 2. 1 indexed citations

Rubinstein, Jeremy D., et al.. (2023). Use of gemcitabine, oxaliplatin, and anti‐CD20 therapy in children and adolescents with non‐Hodgkin lymphoma unfit for intensive therapy. Pediatric Blood & Cancer. 70(4). e30214–e30214. 2 indexed citations

Rubinstein, Jeremy D. & Maureen M. O’Brien. (2023). Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations. Frontiers in Immunology. 14. 1237738–1237738. 12 indexed citations

10.

Brivio, Erica, Harm van Tinteren, Susan R. Rheingold, et al.. (2022). Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia. 37(1). 53–60. 13 indexed citations

11.

Sabulski, Anthony, David D. Grier, Kasiani C. Myers, Stella M. Davies, & Jeremy D. Rubinstein. (2022). Acute myeloid leukemia in SRP54‐mutated congenital neutropenia. SHILAP Revista de lepidopterología. 3(2). 521–525. 5 indexed citations

12.

Rubinstein, Jeremy D., Carolyn Lutzko, Tom Leemhuis, et al.. (2021). Scheduled Donor-Derived Viral Specific T-Cells for Prophylaxis Against Double Stranded DNA Viral Infection after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 27(3). S87–S88. 1 indexed citations

13.

Rubinstein, Jeremy D., Sonata Jodele, Jamie Wilhelm, et al.. (2021). Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients. Transplantation and Cellular Therapy. 28(2). 116.e1–116.e7. 17 indexed citations

14.

Rubinstein, Jeremy D., et al.. (2020). Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis. Pediatric Blood & Cancer. 68(3). e28852–e28852. 2 indexed citations

15.

Rubinstein, Jeremy D., Christa Krupski, William J. O’Brien, et al.. (2020). Chimeric antigen receptor T‐cell therapy in patients with neurologic comorbidities. Pediatric Blood & Cancer. 67(4). e28199–e28199. 10 indexed citations

16.

Rubinstein, Jeremy D., Christa Krupski, Adam Nelson, et al.. (2020). Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. Biology of Blood and Marrow Transplantation. 26(11). e280–e285. 28 indexed citations

17.

Lucas, Donald J., Jeremy D. Rubinstein, Ankush Gosain, et al.. (2019). Surgical and anesthetic management for hepatectomy in two pediatric patients with trisomy 18, pulmonary hypertension, and hepatoblastoma. Pediatric Blood & Cancer. 66(6). e27678–e27678. 8 indexed citations

18.

Elagib, Kamaleldin E., Jeremy D. Rubinstein, Lorrie L. Delehanty, et al.. (2013). Calpain 2 Activation of P-TEFb Drives Megakaryocyte Morphogenesis and Is Disrupted by Leukemogenic GATA1 Mutation. Developmental Cell. 27(6). 607–620. 24 indexed citations

19.

Rubinstein, Jeremy D., Kamaleldin E. Elagib, & Adam N. Goldfarb. (2012). Cyclic AMP Signaling Inhibits Megakaryocytic Differentiation by Targeting Transcription Factor 3 (E2A) Cyclin-dependent Kinase Inhibitor 1A (CDKN1A) Transcriptional Axis. Journal of Biological Chemistry. 287(23). 19207–19215. 8 indexed citations

20.

Borland, Maria, Kochupurackal P. Mohanakumar, Jeremy D. Rubinstein, et al.. (2008). Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1792(1). 68–74. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact